Roche Applied Science Genome Sequencer FLX+

454 FLX+ is an advanced next-generation DNA sequencing system developed by 454 Life Sciences, a subsidiary of Roche Applied Science. Launched in 2011, this instrument was renowned for its ability to generate exceptionally long sequencing reads, reaching up to 1,000 base pairs, thereby enhancing the accuracy and efficiency of genomic analyses.

Key features include:

• Extended read lengths: Achieves up to 1,000 base pairs per read, facilitating comprehensive genome assemblies.
• High throughput: Capable of producing hundreds of millions of bases per run, suitable for large-scale projects.
• Versatile applications: Supports de novo sequencing, transcriptome profiling, metagenomics, and targeted resequencing.
• Enhanced accuracy: Delivers high-quality data with consensus accuracy exceeding 99.99%.

This system was widely adopted in various scientific fields, including genomics, transcriptomics, metagenomics, and clinical research. It found applications in university laboratories, biomedical research centres, and clinical diagnostics facilities. Notably, institutions like the University of Barcelona and BGI integrated the 454 FLX+ into their research infrastructures to advance genomic studies. ([selectscience.net](https://www.selectscience.net/article/454-sequencing-boosts-genomics-research-in-spain-genome-sequencer-flx-system-installed-at-university-of-barcelona?utm_source=openai), [prnewswire.com](https://www.prnewswire.com/news-releases/bgi-installs-roche-gs-flx-system-to-enhance-long-read-sequencing-capabilities-for-genome-and-transcriptome-research-151510855.html?utm_source=openai))

Despite its significant contributions, Roche announced the discontinuation of the 454 platform in 2013, with support ceasing by mid-2016, as newer sequencing technologies emerged.